Please assess the completion status of the following clinical trial:

Trial Title: Alefacept (Amevive) With or Without Narrowband UVB Treatment in Patients With Psoriasis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe plaque-type psoriasis;~* disease duration for more than 6 months~* PASI above 10.~Exclusion Criteria:~* age \< 18 years;~* pregnancy or lactation;~* presence of a dysplastic nevus syndrome;~* photosensitive skin disease;~* autoimmune disease;~* severe renal or hepatic disease;~* presence or history of malignant skin tumors;~* presence of antinuclear antibodies;~* history of previous treatments with arsenic, methotrexate, or x-rays;~* within the last 4 weeks before enrollment into the study, UVB or PUVA treatment, immunosuppressive/-modulating drugs (such as corticosteroids, cyclosporine, and biologics such as infliximab, etanercept or efalizumab).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).